RenovoRx (RNXT) H.C. Wainwright 28th Annual Global Investment Conference summary

Technology and clinical innovation

• Introduced a proprietary drug delivery system, RenovoCath, now commercialized in 21+ centers, targeting hypovascular tumors like pancreatic cancer.

• The TAMP mechanism delivers high drug concentrations to tumors while reducing systemic toxicity, with studies showing up to 100x tissue concentration and 50% less systemic exposure.

• Outpatient procedure with conscious sedation, requiring eight treatments over four months, and simple physician training.

• Phase III TIGeR-PaC trial completed enrollment, with interim data showing a six-month survival benefit and 65% reduction in systemic toxicities.

• Expansion into other cancers, including bile duct and metastatic pancreatic cancer, with multiple investigator-initiated trials underway.

Commercial progress and market opportunity

• Commercial launch of RenovoCath device with rapid adoption, aiming for over 35 centers by year-end and a $400 million peak sales opportunity.

• High-margin business model (85% gross, 30% operating margins), with $6,000–$8,500 per unit and average six treatments per patient.

• Lean sales force covers the concentrated U.S. market, with 63 centers in the pipeline and increasing commercial penetration.

• Q2 revenue reached $909,000, a 115% YoY increase, and 61% sequential growth; first half revenue was $1.5 million, up 138% YoY.

• Revenue guidance raised to $3.75–$4.25 million for the year, driven by new center adoption and transition of trial sites to commercial customers.

Strategic outlook and leadership

• Patent portfolio includes 20 issued and 13 pending patents, securing exclusivity through 2045.

• Experienced leadership and advisory boards span clinical, commercial, and scientific expertise, supporting both device and drug development.

• Ongoing post-market and investigator-initiated studies generate both revenue and clinical data.

• Anticipated milestones include first treatments in new trials, additional data releases, and top-line phase III results in the second half of next year.

• Strong patient impact and positive media coverage are fueling commercial adoption and business growth.